saxenda glp 1 (liraglutide) for the Treatment of Obesity, US Teva Claims A First With

Obesity independently increases cardiovascular mortality, and weight loss of 5 to 10% yields meaningful reductions in cardiovascular disease risk factors

, liraglutide administered to mice with hypertension induced by angiotensin II also normalized blood pressure, which resulted in reduced cardiac hypertrophy and a reduced heart/body weight ratio, both parameters indicative of hypertensive heart disease

Ann Intern Med 176(3):427429

Risk of fracture in women with type 2 diabetes: the women's health initiative observational study

Fibre also: Slows digestion Supports gut microbiome health Reduces constipation, which can be a side effect of GLP-1 agonists 3